Clinical Trials on Peripheral T-cell Lymphoma

Total 7546 results

University of Alabama at Birmingham

Terminated

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Not yet recruiting

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Peripheral T-cell Lymphomas (PTCL)

Taiwan
Ontario Clinical Oncology Group (OCOG)
Sunnybrook Health Sciences Centre; Genzyme, a Sanofi Company

Completed

Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas (ACCAPELA)

Peripheral T-cell Lymphomas

Canada
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Immune System Diseases | Lymphoproliferative Disorders | Peripheral T-cell Lymphomas

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas (FIL_PTCL13)

Peripheral T-cell Lymphomas (PTCL) | PTCL-NOS | Angioimmunoblastic T-cell Lymphoma (AITL) | ALK- Anaplastic Large Cell Lymphoma (ALCL) | Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin

Italy
Nanjing NingQi Medicine Science and Technology...
Jiangsu Cancer Institute & Hospital

Unknown

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Peripheral T-cell Lymphomas

China
Kyowa Kirin Co., Ltd.

Completed

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

Adult T-Cell Leukemia and Lymphoma (ATL) | Adult Peripheral T-Cell Lymphoma (PTCL)

Japan
Samsung Medical Center
Janssen Medical Affairs

Completed

Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

Non-Hodgkin Lymphoma | Peripheral T-Cell Lymphomas

Korea, Republic of
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
Ohio State University Comprehensive Cancer Center
Celgene Corporation

Recruiting

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Cutaneous T-cell Lymphoma | Peripheral T-Cell Lymphoma | T-Prolymphocytic Leukemia | T-Large Granulocytic Leukemia | T-Lymphoblastic Leukemia/Lymphoma

United States
Celgene

Completed

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Peripheral T-cell Lymphoma | Adult T-cell Leukemia-Lymphoma

Japan
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell Lymphoma

China
Portola Pharmaceuticals

Withdrawn

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

AITL | Peripheral T-Cell Lymphoma (PTCL NOS) | Nodal Lymphomas of T Follicular Helper (TFH) | Follicular T-cell Lymphoma (FTCL) | ALCL | HSTCL | EATL I,II | MEITL, EATL Type II | Nasal Lymphoma
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC; National Medical Research Council (NMRC), Singapore

Not yet recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

Singapore
The Lymphoma Academic Research Organisation

Completed

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

France, Belgium
Millennium Pharmaceuticals, Inc.

Completed

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

United States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
Shanghai General Hospital, Shanghai Jiao Tong University...

Suspended

Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies

Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | Anaplastic Lymphoma | Acute T Cell Leukemia | T-lymphoblastic Lymphoma

China
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co, Ltd. China

Unknown

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | NK/T-cell Lymphoma | Adult T-Cell Lymphoma/Leukaemia

China
National Cancer Institute (NCI)

Completed

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Peripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)

United States
Legend Biotech USA Inc

Active, not recruiting

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

T-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma Recurrent

United States
Karyopharm Therapeutics Inc

Terminated

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)

Australia, Singapore
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Japan
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis (CUTALLO)

Epidermotropic T-cell Lymphomas

France
Angimmune LLC
M.D. Anderson Cancer Center; Yale University; University of Texas Southwestern... and other collaborators

Completed

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

Mycosis Fungoides | Sezary Syndrome | T-cell Lymphomas | T-cell Leukemia | Cutaneous T-cell Lymphoma (CTCL)

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

T-cell Large Granular Lymphocyte Leukemia | T-cell Lymphomas | T-cell Prolymphocytic Leukemia | NK-Cell Lymphomas

United States
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
M.D. Anderson Cancer Center
Takeda

Withdrawn

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Anaplastic Large Cell Lymphoma | Classical Hodgkin Lymphoma | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | CD30+ Peripheral T-cell Lymphoma
Onxeo

Terminated

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas (PXD101-CLN-6)

Non-Hodgkin's Lymphoma | Cutaneous T-Cell Lymphoma | Peripheral T-Cell Lymphoma

United States, Germany, Israel, France, Thailand
SciTech Development, LLC
Rush University Medical Center

Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Mycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditions

United States
M.D. Anderson Cancer Center

Completed

A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma

United States
Samsung Medical Center
National Cancer Center, Korea; Asan Medical Center; Yonsei University; Korea Cancer...

Completed

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas (RADCHOP)

Cutaneous T Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-negative | Angioimmunoblastic T Cell Lymphoma | Peripheral T Cell Lymphoma Unspecified

Korea, Republic of
Acrotech Biopharma Inc.

Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO)

Peripheral T Cell Lymphoma

United States
Zhao Weili

Not yet recruiting

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Ruijin Hospital
RenJi Hospital; West China Hospital; Shandong Provincial Hospital; Tianjin Medical... and other collaborators

Not yet recruiting

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)

Peripheral T Cell Lymphoma

China
Second Affiliated Hospital, School of Medicine,...
Ningbo No. 1 Hospital; Jinhua Central Hospital; Huizhou Municipal Central Hospital

Recruiting

A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

China
Henan Cancer Hospital

Recruiting

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Innate Pharma

Completed

Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Peripheral T Cell Lymphoma

Korea, Republic of, United States
University of Colorado, Denver
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Peripheral T Cell Lymphoma

United States
Conjupro Biotherapeutics, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Withdrawn

PLM60 for Peripheral T Cell Lymphoma (PTCL)

Peripheral T Cell Lymphoma

United States
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma
Zhejiang Cancer Hospital

Unknown

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

China
Eisai Co., Ltd.

Completed

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Peripheral T-Cell Lymphoma

Japan
The University of Hong Kong

Unknown

Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

Peripheral T Cell Lymphoma

Hong Kong
The First Affiliated Hospital of Soochow University

Unknown

Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) (CHOP)

Peripheral T Cell Lymphoma

China
H. Lee Moffitt Cancer Center and Research Institute
Seagen Inc.

Terminated

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Peripheral T-Cell Lymphoma

United States
Nanfang Hospital of Southern Medical University

Unknown

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Peripheral T Cell Lymphoma

China
Kyowa Hakko Kirin Pharma, Inc.

Completed

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Peripheral T-Cell Lymphoma

France, United Kingdom, Netherlands, Denmark, Italy, Spain
University Hospital, Grenoble
French Innovative Leukemia Organisation

Completed

Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma (LTP)

Peripheral T Cell Lymphoma

France
Mahidol University
Bayer

Terminated

The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

Peripheral T-Cell Lymphoma

Thailand

Clinical Trials on Peripheral T-cell Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations